Probenecid for Opioid Withdrawal

Phase 2

Recruiting

Led By Lori Montgomery, MD

Research Sponsored by University of Calgary

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Capable of providing informed consent

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 years

Summary

This trial looks to help people suffering from opioid withdrawal by using an existing drug, probenecid, to block a protein in the spinal cord responsible for withdrawal symptoms.

Who is the study for?

Adults over 18 with chronic pain, currently on daily opioid medication and planning to reduce their dose. They must have a kidney function test (GFR) above 50 mL/min and be able to give informed consent. The trial is not suitable for those who cannot voluntarily decrease their opioid use or have other health issues that the study doesn't list.

What is being tested?

The trial tests Probenecid's effectiveness in easing symptoms of opioid withdrawal in patients dependent on opioids due to chronic pain management. It explores whether this already approved drug can block certain proteins involved in withdrawal symptoms.

What are the potential side effects?

While specific side effects are not listed here, Probenecid is generally considered safe but could potentially cause allergic reactions, gastrointestinal discomfort, headache, dizziness, or increase the risk of gout.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I can understand and agree to the study's details.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

To evaluate acceptability of oral probenecid in patients undergoing voluntary opioid tapering

To evaluate safety of oral probenecid in patients undergoing voluntary

To evaluate tolerability of oral probenecid in patients undergoing voluntary opioid tapering

Secondary study objectives

To evaluate the feasibility of treatment with probenecid in a patient-directed opioid tapering protocol, in the setting of an interdisciplinary pain clinic

To evaluate whether Panx1 gene variants correlate with opioid withdrawal severity and response to probenecid by collecting salivary samples and performing DNA extraction in a small cohort.